Adhesive CapsulitisCSvsCSHDNCT06493656
Isolated Glenohumeral Corticosteroid Injection Versus Concomitant Capsule Preserving Hydrodilatation
A study testing Ultrasound-guided glenohumeral space isolated corticosteroid injection, Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injection and 1mL of Triamcinolone (40mg/1mL) Injectable Solution in people with Adhesive Capsulitis and Adhesive Capsulitis of Shoulder, run by Chuncheon Sacred Heart Hospital at 1 site in South Korea.
Trial summary
This clinical trial investigates whether concomitant capsule-preserving hydrodilatation (CSHD) is more effective than isolated glenohumeral corticosteroid injection (CS) in treating shoulder adhesive capsulitis. Read more about this study
- Who is it for?
- Ages 35 to 80 years
- Conditions the study is for
- Adhesive Capsulitis, Adhesive Capsulitis of Shoulder
- What is being tested?
- Ultrasound-guided glenohumeral space isolated corticosteroid injection, Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injection and 1mL of Triamcinolone (40mg/1mL) Injectable Solution
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteSouth Korea
- Study dates
- 5 Dec 2013to 17 Nov 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Two or more of the following criteria within the shoulder's range of motion:
- Abduction and forward elevation below 100˚
- External rotation at the side below 30˚
- Internal rotation at 90˚ of abduction below 30˚
Who cannot join
- History of shoulder surgery, trauma, nerve injury
- Concomitant rotator cuff/biceps lesions in ultrasound or MRI
- Glenohumeral arthritis in simple X-ray
- Calcific tendinosis in simple X-ray
- Underlying conditions: cancer, mental illness, hormonal imbalance
- Diabetes with HbA1c levels exceeding 7.0%
Trial locations and contacts
1 site in 1 country.
South Korea1 site
Chuncheon Sacred Heart Hospital
Chuncheon, Gangwondo, 700-204
About this study
Official title: The Efficacy of Single-shot Capsule-preserving Hydrodilatation With Corticosteroids in Treating Adhesive Capsulitis of the Shoulder: A Randomized Controlled Trial Versus Isolated Corticosteroid Injection
This clinical trial investigates whether concomitant capsule-preserving hydrodilatation (CSHD) is more effective than isolated glenohumeral corticosteroid injection (CS) in treating shoulder adhesive capsulitis. The main questions it aims to answer are
- Is CSHD inferior to CS in immediate pain relief as the solution is diluted?
- Is CSHD superior to CS in improving the range of motion as the contracted capsule is dilated?
Read more
Group CS will receive an ultrasound-guided glenohumeral corticosteroid injection only, with a solution of 5 mL.
Group CSHD will receive an ultrasound-guided glenohumeral corticosteroid with hydrodilatation, with a solution of 20 mL.
Clinical scores and range of motion will be compared between the groups up to six months post-injection.
Read the detailed description
A single-centre, double-blinded, prospective randomised controlled trial involving patients diagnosed with adhesive capsulitis of the shoulder (AC).
Patients were randomly allocated to either corticosteroid injection with hydrodilatation (group CSHD) or corticosteroid injection only (group CS).
For the CS group, a solution of 1 mL triamcinolone (40mg) and 4 mL 1% lidocaine, 5 mL in total, was injected intraarticularly through the posterior approach using ultrasound guidance.
The CSHD group received an injection of 20 mL with 15 mL of normal saline added to the abovementioned 5 mL solution. The dilatation of the joint capsule was confirmed by the increase in distance between the capsule and the humeral head.
Patients underwent the following assessments just before the injection, and at post-injection three weeks, seven weeks, three months, and six months.
Range of motion in forward elevation, external rotation, and internal rotation Clinical scores include the pain visual analogue scale (pVAS), the American Shoulder and Elbow Surgeons score, and the Constant-Murley score.
Subjective patient satisfaction was recorded on a scale from 0 to 100, with 100 being the most satisfied.
The recorded data were compared within each group before and after the injection, and also between the groups.
- Being tested
- Ultrasound-guided glenohumeral space isolated corticosteroid injection, Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injection, 1mL of Triamcinolone (40mg/1mL) Injectable Solution, 4mL of Lidocaine 1% Solution Injectable Solution, 15mL of Normal Saline
- Keywords
- Glenohumeral injection, Hydrodilatation, Corticosteroid injection
- Medical subject headings
- Bursitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ultrasound-guided glenohumeral space isolated corticosteroid injectionProcedure or surgery
Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.
Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injectionProcedure or surgery
Using a 21-gauge spinal needle, the predefined steroid solution with additional 15 mL of normal saline was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.
1mL of Triamcinolone (40mg/1mL) Injectable SolutionDrug
1mL of Triamcinolone 40mg/1mL solution was included in the injection/hydrodilatation regimen.
4mL of Lidocaine 1% Solution Injectable SolutionDrug
4mL of 1% Lidocaine solution was included in the injection/hydrodilatation regimen.
15mL of Normal SalineDrug
15mL of 1% Lidocaine solution was included in the hydrodilatation regimen.
| Study group | Role | What they receive |
|---|---|---|
| Isolated corticosteroid injection | Experimental | Ultrasound-guided posterior approach of glenohumeral space injection for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine. Receives: Procedure: Ultrasound-guided glenohumeral space isolated corticosteroid injection; Drug: 1mL of Triamcinolone (40mg/1mL) Injectable Solution; Drug: 4mL of Lidocaine 1% Solution Injectable Solution |
| Concomitant hydrodilatation with corticosteroid injection | Active comparator | Ultrasound-guided posterior approach of glenohumeral space hydrodilatation for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, and 15 mL normal saline Receives: Procedure: Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injection; Drug: 1mL of Triamcinolone (40mg/1mL) Injectable Solution; Drug: 4mL of Lidocaine 1% Solution Injectable Solution; Drug: 15mL of Normal Saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
American Shoulder and Elbow Surgeons (ASES) shoulder score
Patient-reported shoulder satisfaction score, 0-100, higher scores mean a better outcome.
Measured: Change from the baseline to 7 weeks
Secondary outcomes (3)
Range of motion (ROM)
ROM in degrees, forward elevation (0-150), external rotation (0-90), and internal rotation (0-90)
Measured: Change from the baseline to 6 months
Visual analog scale (VAS) for pain
Patient-reported 0-10 scale of pain, 0: no pain, 10: very severe pain
Measured: Change from the baseline to 6 months
Constant-Murley score
Patient-reported and healthcare provider-assessed shoulder satisfaction score, 0-100, higher scores mean a better outcome.
Measured: Change from the baseline to 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2024
- Study start5 Dec 2013
- Primary completion17 Nov 2015
- Study completion17 Nov 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Adhesive CapsulitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Study group underwent ultrasound-guided posterior approach of glenohumeral space injection for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 7 mL normal saline. Control group underwent ultrasound-guided posterior approach of glenohumeral space HYDRODILATATION for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 15 mL normal saline.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chuncheon Sacred Heart Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jung-Taek Hwang, Chuncheon Sacred Heart Hospital
- Investigators
- Jung Taek Hwang, MD, PhD, Principal investigator, Chuncheon Sacred Heart Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06493656
- Sponsor's protocol ID
- CSvsCSHD
- Acronym
- CSvsCSHD
- Status last verified
- Jul 2026
- First submitted
- 24 Jun 2024
- Last updated
- 9 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Neviaser AS, Hannafin JA. Adhesive capsulitis: a review of current treatment. Am J Sports Med. 2010 Nov;38(11):2346-56. doi: 10.1177/0363546509348048. Epub 2010 Jan 28.
PubMed 20110457Cho CH, Lee YH, Kim DH, Lim YJ, Baek CS, Kim DH. Definition, Diagnosis, Treatment, and Prognosis of Frozen Shoulder: A Consensus Survey of Shoulder Specialists. Clin Orthop Surg. 2020 Mar;12(1):60-67. doi: 10.4055/cios.2020.12.1.60. Epub 2020 Feb 13.
PubMed 32117540Redler LH, Dennis ER. Treatment of Adhesive Capsulitis of the Shoulder. J Am Acad Orthop Surg. 2019 Jun 15;27(12):e544-e554. doi: 10.5435/JAAOS-D-17-00606.
PubMed 30632986Catapano M, Mittal N, Adamich J, Kumbhare D, Sangha H. Hydrodilatation With Corticosteroid for the Treatment of Adhesive Capsulitis: A Systematic Review. PM R. 2018 Jun;10(6):623-635. doi: 10.1016/j.pmrj.2017.10.013. Epub 2017 Nov 10.
PubMed 29129609Oh JH, Oh CH, Choi JA, Kim SH, Kim JH, Yoon JP. Comparison of glenohumeral and subacromial steroid injection in primary frozen shoulder: a prospective, randomized short-term comparison study. J Shoulder Elbow Surg. 2011 Oct;20(7):1034-40. doi: 10.1016/j.jse.2011.04.029. Epub 2011 Aug 4.
PubMed 21816628Kim DY, Lee SS, Nomkhondorj O, Cho MG, Lee JJ, Hwang JT, Hong MS. Comparison Between Anterior and Posterior Approaches for Ultrasound-Guided Glenohumeral Steroid Injection in Primary Adhesive Capsulitis: A Randomized Controlled Trial. J Clin Rheumatol. 2017 Jan;23(1):51-57. doi: 10.1097/RHU.0000000000000475. No abstract available.
PubMed 28002160Kim YT, Hwang JT, Han SH, Hong MS, Lee JB. Simplified, single-shot, capsule-preserving hydrodilatation combined with corticosteroids versus isolated corticosteroid injection for adhesive capsulitis: a randomized controlled trial. J Orthop Surg Res. 2026 Sep 6;21(1):613. doi: 10.1186/s13018-026-07215-2.
PubMed 42947148
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Efficacy of Single-shot Capsule-preserving Hydrodilatation With Corticosteroids in Treating Adhesive Capsulitis of the Shoulder: A Randomized Controlled Trial Versus Isolated Corticosteroid Injection
- ClinicalTrials.gov ID
- NCT06493656
- Acronym / sponsor ID
- CSvsCSHD / CSvsCSHD
- Keywords
- Glenohumeral injection, Hydrodilatation, Corticosteroid injection
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Chuncheon Sacred Heart HospitalUniversity, hospital or other
- Study start
- 5 Dec 2013 (actual)
- Primary completion
- 17 Nov 2015 (actual)
- Study completion
- 17 Nov 2015 (actual)
- First posted
- 10 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial investigates whether concomitant capsule-preserving hydrodilatation (CSHD) is more effective than isolated glenohumeral corticosteroid injection (CS) in treating shoulder adhesive capsulitis. The main questions it aims to answer are
- Is CSHD inferior to CS in immediate pain relief as the solution is diluted?
- Is CSHD superior to CS in improving the range of motion as the contracted capsule is dilated?
Group CS will receive an ultrasound-guided glenohumeral corticosteroid injection only, with a solution of 5 mL.
Group CSHD will receive an ultrasound-guided glenohumeral corticosteroid with hydrodilatation, with a solution of 20 mL.
Clinical scores and range of motion will be compared between the groups up to six months post-injection.
Detailed description
A single-centre, double-blinded, prospective randomised controlled trial involving patients diagnosed with adhesive capsulitis of the shoulder (AC).
Patients were randomly allocated to either corticosteroid injection with hydrodilatation (group CSHD) or corticosteroid injection only (group CS).
For the CS group, a solution of 1 mL triamcinolone (40mg) and 4 mL 1% lidocaine, 5 mL in total, was injected intraarticularly through the posterior approach using ultrasound guidance.
The CSHD group received an injection of 20 mL with 15 mL of normal saline added to the abovementioned 5 mL solution. The dilatation of the joint capsule was confirmed by the increase in distance between the capsule and the humeral head.
Patients underwent the following assessments just before the injection, and at post-injection three weeks, seven weeks, three months, and six months.
Range of motion in forward elevation, external rotation, and internal rotation Clinical scores include the pain visual analogue scale (pVAS), the American Shoulder and Elbow Surgeons score, and the Constant-Murley score.
Subjective patient satisfaction was recorded on a scale from 0 to 100, with 100 being the most satisfied.
The recorded data were compared within each group before and after the injection, and also between the groups.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Study group underwent ultrasound-guided posterior approach of glenohumeral space injection for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 7 mL normal saline. Control group underwent ultrasound-guided posterior approach of glenohumeral space HYDRODILATATION for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 15 mL normal saline.
| Arm | Type | Receives |
|---|---|---|
| Isolated corticosteroid injection | Experimental | Procedure: Ultrasound-guided glenohumeral space isolated corticosteroid injection, Drug: 1mL of Triamcinolone (40mg/1mL) Injectable Solution, Drug: 4mL of Lidocaine 1% Solution Injectable SolutionUltrasound-guided posterior approach of glenohumeral space injection for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine. |
| Concomitant hydrodilatation with corticosteroid injection | Active comparator | Procedure: Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injection, Drug: 1mL of Triamcinolone (40mg/1mL) Injectable Solution, Drug: 4mL of Lidocaine 1% Solution Injectable Solution, Drug: 15mL of Normal SalineUltrasound-guided posterior approach of glenohumeral space hydrodilatation for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, and 15 mL normal saline |
Who may qualify
- Ages
- 35 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Abduction and forward elevation below 100˚
- External rotation at the side below 30˚
- Internal rotation at 90˚ of abduction below 30˚
Key exclusion criteria (6 listed)
- History of shoulder surgery, trauma, nerve injury
- Concomitant rotator cuff/biceps lesions in ultrasound or MRI
- Glenohumeral arthritis in simple X-ray
- Calcific tendinosis in simple X-ray
- Underlying conditions: cancer, mental illness, hormonal imbalance
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ultrasound-guided glenohumeral space isolated corticosteroid injectionUsing a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach. | Procedure or surgery | Isolated corticosteroid injection |
| Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injectionUsing a 21-gauge spinal needle, the predefined steroid solution with additional 15 mL of normal saline was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach. | Procedure or surgery | Concomitant hydrodilatation with corticosteroid injection |
| 1mL of Triamcinolone (40mg/1mL) Injectable Solution1mL of Triamcinolone 40mg/1mL solution was included in the injection/hydrodilatation regimen. | Drug | Concomitant hydrodilatation with corticosteroid injection, Isolated corticosteroid injection |
| 4mL of Lidocaine 1% Solution Injectable Solution4mL of 1% Lidocaine solution was included in the injection/hydrodilatation regimen. | Drug | Concomitant hydrodilatation with corticosteroid injection, Isolated corticosteroid injection |
| 15mL of Normal Saline15mL of 1% Lidocaine solution was included in the hydrodilatation regimen. | Drug | Concomitant hydrodilatation with corticosteroid injection |
Primary outcome
American Shoulder and Elbow Surgeons (ASES) shoulder score
Time frame: Change from the baseline to 7 weeks
Patient-reported shoulder satisfaction score, 0-100, higher scores mean a better outcome.
3 secondary outcomes
Range of motion (ROM)
Time frame: Change from the baseline to 6 months
Visual analog scale (VAS) for pain
Time frame: Change from the baseline to 6 months
Constant-Murley score
Time frame: Change from the baseline to 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2026.
- Results publication: PubMed 20110457Neviaser AS, Hannafin JA. Adhesive capsulitis: a review of current treatment. Am J Sports Med. 2010 Nov;38(11):2346-56. doi: 10.1177/0363546509348048. Epub 2010 Jan 28.
- Results publication: PubMed 32117540Cho CH, Lee YH, Kim DH, Lim YJ, Baek CS, Kim DH. Definition, Diagnosis, Treatment, and Prognosis of Frozen Shoulder: A Consensus Survey of Shoulder Specialists. Clin Orthop Surg. 2020 Mar;12(1):60-67. doi: 10.4055/cios.2020.12.1.60. Epub 2020 Feb 13.
- Results publication: PubMed 30632986Redler LH, Dennis ER. Treatment of Adhesive Capsulitis of the Shoulder. J Am Acad Orthop Surg. 2019 Jun 15;27(12):e544-e554. doi: 10.5435/JAAOS-D-17-00606.
- Results publication: PubMed 29129609Catapano M, Mittal N, Adamich J, Kumbhare D, Sangha H. Hydrodilatation With Corticosteroid for the Treatment of Adhesive Capsulitis: A Systematic Review. PM R. 2018 Jun;10(6):623-635. doi: 10.1016/j.pmrj.2017.10.013. Epub 2017 Nov 10.
- Results publication: PubMed 21816628Oh JH, Oh CH, Choi JA, Kim SH, Kim JH, Yoon JP. Comparison of glenohumeral and subacromial steroid injection in primary frozen shoulder: a prospective, randomized short-term comparison study. J Shoulder Elbow Surg. 2011 Oct;20(7):1034-40. doi: 10.1016/j.jse.2011.04.029. Epub 2011 Aug 4.
- Results publication: PubMed 28002160Kim DY, Lee SS, Nomkhondorj O, Cho MG, Lee JJ, Hwang JT, Hong MS. Comparison Between Anterior and Posterior Approaches for Ultrasound-Guided Glenohumeral Steroid Injection in Primary Adhesive Capsulitis: A Randomized Controlled Trial. J Clin Rheumatol. 2017 Jan;23(1):51-57. doi: 10.1097/RHU.0000000000000475. No abstract available.
- Derived from this study: PubMed 42947148Kim YT, Hwang JT, Han SH, Hong MS, Lee JB. Simplified, single-shot, capsule-preserving hydrodilatation combined with corticosteroids versus isolated corticosteroid injection for adhesive capsulitis: a randomized controlled trial. J Orthop Surg Res. 2026 Sep 6;21(1):613. doi: 10.1186/s13018-026-07215-2.
- Individual participant dataSharing planned: No
Related trials for Adhesive Capsulitis
Not yet recruiting
Effects of Clinic Versus mHealth Application-Based Shoulder Rehabilitation in Patients With Adhesive Capsulitis
Adhesive Capsulitis
Not yet recruiting
Effect of Hormone Replacement Therapy on Physiotherapy Outcomes in Postmenopausal Women With Frozen Shoulder
Frozen Shoulder, Adhesive Capsulitis
Not yet recruiting
Effects of Posterior Capsular Stretching With and Without Dynamic Neuromuscular Stabilization Exercises in Frozen Shoulder
Frozen Shoulder
Active, not recruiting
Spencer vs. Ola Grimsby Techniques With Scapular Motor Training in Idiopathic Adhesive Capsulitis
Idiopathic Adhesive Capsulitis
Not yet recruitingPhase 4
OMT for Adhesive Capsulitis
Adhesive Capsulitis of the Shoulder, Frozen Shoulder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jung Taek Hwang, MD, PhD principal investigator
Chuncheon Sacred Heart Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ultrasound-guided glenohumeral space isolated corticosteroid injection, Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injection and 1mL of Triamcinolone (40mg/1mL) Injectable Solution in people with Adhesive Capsulitis and Adhesive Capsulitis of Shoulder, run by Chuncheon Sacred Heart Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
American Shoulder and Elbow Surgeons (ASES) shoulder score (time frame: Change from the baseline to 7 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06493656, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026.